The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
MDS 2023 | Combining molecular and clinical data to predict survival & transformation risk in patients with MDS
Matteo Della Porta, MD, IRCCS Humanitas Research Hospital, Milan, Italy, comments on the current shift in risk stratification methods for patients with myelodysplastic syndromes (MDS). Prof. Della Porta explains that next-generation prognostic tools, which combine clinical and molecular data, provide more genomic information than conventional tools and can more accurately define a patient’s overall survival (OS) and risk of disease progression. This interview took place at the 17th International Congress on Myelodysplastic Syndromes (MDS) 2023, held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
